Harmony Biosciences (HRMY) Scheduled to Post Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) will be announcing its earnings results before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.29). Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. The business had revenue of $168.40 million during the quarter, compared to analyst estimates of $168.90 million. During the same period in the previous year, the business earned $1.01 earnings per share. The business’s quarterly revenue was up 31.3% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Harmony Biosciences Stock Down 0.2 %

HRMY opened at $29.35 on Tuesday. Harmony Biosciences has a 1-year low of $18.61 and a 1-year high of $39.26. The stock has a market cap of $1.67 billion, a PE ratio of 13.84, a price-to-earnings-growth ratio of 0.41 and a beta of 0.73. The stock’s fifty day simple moving average is $31.76 and its 200 day simple moving average is $30.04. The company has a current ratio of 2.75, a quick ratio of 2.72 and a debt-to-equity ratio of 0.38.

Insider Activity

In other Harmony Biosciences news, insider Jeffrey Dierks sold 11,979 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $32.00, for a total value of $383,328.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 30.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HRMY shares. Mizuho decreased their target price on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $49.00 price target on shares of Harmony Biosciences in a research note on Friday, April 12th. The Goldman Sachs Group increased their target price on shares of Harmony Biosciences from $25.00 to $28.00 and gave the stock a “sell” rating in a research report on Tuesday, January 9th. Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 9th. Finally, Bank of America restated an “underperform” rating and issued a $30.00 price target on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Harmony Biosciences has an average rating of “Moderate Buy” and an average target price of $40.63.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.